The deal adds a pipeline targeting the antibodies behind Graves’ disease, thyroid eye disease, food allergy, and other conditions
Important BUY LLY Stage 2 (Conv: 5/5 | Size: 20%)
Eli Lilly is buying a biotech startup for nearly $3 billion to expand into autoimmune diseases
The deal adds a pipeline targeting the antibodies behind Graves’ disease, thyroid eye disease, food allergy, and other conditions Source: Read the original article on qz.com
